

Analysts initiated coverage on NHP (Outperform, $20), OIG (Buy, $13), ETRA (Overweight), AHR (Strong Buy, $62).
You can purchase shares of Electra Therapeutics (NASDAQ:ETRA) through any online brokerage.
Other companies in Electra Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Electra Therapeutics has a consensus price target of $34.67.
The stock price for Electra Therapeutics (NASDAQ: ETRA) is $9.48 last updated October 23, 2026 at 8:13 AM EDT.
There are no upcoming dividends for Electra Therapeutics.
Electra Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Electra Therapeutics.
Electra Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.